Eurofins Stock Climbs 2.5% and Ranks Among Top Performers in the CAC 40
The Luxembourg-based bioanalytical testing specialist marks another session of gains in Paris. The stock continues the momentum started the previous day and ranks among the top performances of the CAC 40, which ends with a moderate increase. The movement comes following a reiterated bearish outlook by a major American broker.
The stock ranks among the top performances of the CAC 40 at close
Eurofins Scient. stock gained 2.73% to €67.02, up from €65.24 the previous day. The stock is among the highest risers in the CAC 40, which closed at 8,385.49 points (+0.54%). The increase follows the rebound that began on Tuesday, already reported in a brief from the previous day.
Over the week, the stock has gained 6.86%, and nearly 10.3% over three months, following the April quarterly results which were initially poorly received and had weighed on the price. The SBF 120, meanwhile, ends at 6,330.10 points (+0.42%), while the VIX recedes to 18.38, indicating a relaxation in volatility on the American markets.
The rebound consolidates the exit from the low zone, despite the bearish view from BofA
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price now clearly stands above its three moving averages, with a gap of 5.73% over the MM20 (€63.39) and 6.98% over the MM50 (€62.65). The RSI at 59 remains in the neutral zone, without any overbought signal, which leaves room before the resistance identified at €73.12. This configuration contrasts with the opinion of BofA Securities, which on June 22 maintained its 'sell' recommendation while slightly raising its target from €56 to €58, representing a potential downside of about 13% from the current price. The next technical milestone is at the €73 level, which limits the short-term bullish momentum.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.